BMC MED 2024 10.1186/s12916-024-03638-y
Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers
Lee, JY; Lee, JW; Chung, MS; Choi, JG; Sim, SH; Kim, HJ; Kim, JE; Lee, KE; Park, YH; Kang, MJ; Ahn, MS; Chae, YS; Park, JH; Kim, JH; Kim, GM; Byun, JH; Park, KU; Kim, JW; Jung, SP; Lee, JH; An, JS; Jang, B; Yoon, D; Kim, J; Hong, JS; Koo, H; Cho, KR; Kim, CY; Sa, JK; Park, KH
View PubMed
FUTURE ONCOL 2024 10.1080/14796694.2024.2390791
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
Turner, NC; Oliveira, M; Howell, SJ; Dalenc, F; Cortes, J; Gomez, HL; Hu, XC; Jhaveri, K; Krivorotko, P; Loibl, S; Murillo, SM; Park, YH; Sohn, JH; Toi, M; Tokunaga, E; Yousef, S; Zhukova, L; de Bruin, E; Grinsted, L; Schiavon, G; Foxley, A; Rugo, HS
View PubMed
J CLIN ONCOL 2024 10.1200/JCO.23.02374
Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial
Kang, D; Cho, J; Zhao, D; Kim, J; Kim, N; Kim, H; Kim, S; Kim, JY; Park, YH; Im, YH; Guallar, E; Ahn, JS
View PubMed
ESMO OPEN 2024 10.1016/j.esmoop.2024.103697
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
Rugo, HS; Oliveira, M; Howell, SJ; Dalenc, F; Cortes, J; Gomez, HL; Hu, X; Jhaveri, KL; Krivorotko, P; Loibl, S; Murillo, SM; Nowecki, Z; Okera, M; Park, YH; Sohn, J; Toi, M; Iwata, H; Yousef, S; Zhukova, L; Logan, J; Twomey, K; Khatun, M; D'Cruz, CM; Turner, NC
View PubMed
NPJ BREAST CANCER 2024 10.1038/s41523-024-00679-7
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Im, SA; Cortes, J; Cescon, DW; Yusof, MM; Iwata, H; Masuda, N; Takano, T; Huang, CS; Chung, CF; Tsugawa, K; Park, YH; Matsumoto, K; Inoue, K; Kwong, A; Loi, S; Fu, W; Pan, WL; Karantza, V; Rugo, HS; Schmid, P
View PubMed
LANCET ONCOL 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Oliveira, M; Rugo, HS; Howell, SJ; Dalenc, F; Cortes, J; Gomez, HL; Hu, XC; Toi, M; Jhaveri, K; Krivorotko, P; Loibl, S; Murillo, SM; Okera, M; Nowecki, Z; Park, YH; Sohn, JH; Tokunaga, E; Yousef, S; Zhukova, L; Fulford, M; Andrews, H; Wadsworth, I; D'Cruz, C; Turner, NC
View PubMed
BREAST CANCER RES TR 2024 10.1007/s10549-024-07405-8
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials
Borrego, MR; Lu, YS; Reyes-Cosmelli, F; Park, YH; Yamashita, T; Chiu, J; Airoldi, M; Turner, N; Fein, L; Ghaznawi, F; Singh, J; Pantoja, K; Schnell, C; Akdere, M; Chia, SP
View PubMed
CANCER IMMUNOL IMMUN 2024 10.1007/s00262-024-03782-7
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
Park, C; Suh, KJ; Kim, SH; Lee, KH; Im, SA; Kim, MH; Sohn, J; Jeong, JH; Jung, KH; Lee, KE; Park, YH; Kim, HJ; Cho, EK; Choi, IS; Noh, SJ; Shin, I; Cho, DY; Kim, JH
View PubMed
CANCER METAB 2024 10.1186/s40170-024-00353-3
Real-time assessment of relative mitochondrial ATP synthesis response against inhibiting and stimulating substrates (MitoRAISE)
Chang, ES; Song, K; Song, JY; Sung, M; Lee, MS; Oh, JH; Kim, JY; Park, YH; Jung, K; Choi, YL
View PubMed
SCI REP-UK 2024 10.1038/s41598-024-69614-x
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
Kim, HJ; Yoon, JH; Park, YH
View PubMed
CANCER SCI 2024 10.1111/cas.16234
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Iwata, H; Xu, BH; Kim, SB; Chung, WP; Park, YH; Kim, MH; Tseng, LM; Chung, CF; Huang, CS; Kim, JH; Chiu, JWY; Yamashita, T; Li, W; Egorov, A; Nishijima, S; Nakatani, S; Nishiyama, Y; Sugihara, M; Cortes, J; Im, SA
View PubMed
ANN ONCOL 2024 10.1016/j.annonc.2024.04.001
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
Dent, R; André, F; Gonçalves, A; Martin, M; Schmid, P; Schütz, F; Kümmel, S; Swain, SM; Bilici, A; Loirat, D; Valencia, RV; Im, SA; Park, YH; De Laurentis, M; Colleoni, M; Guarneri, V; Bianchini, G; Li, H; Machackova, ZK; Mouta, J; Deurloo, R; Gan, X; Fan, M; Mani, A; Swat, A; Cortés, J
View PubMed
NPJ BREAST CANCER 2024 10.1038/s41523-024-00669-9
Prognostic value of structural variants in early breast cancer patients
Kim, JY; Park, K; Park, WY; Ahn, JS; Im, YH; Lee, JE; Kim, SW; Nam, SJ; Yu, J; Park, YH
View PubMed
J NATL COMPR CANC NE 2024 10.6004/jnccn.2023.7121
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study
Tan, RYC; Ong, WS; Lee, KH; Park, S; Iqbal, J; Park, YH; Lee, JE; Yu, JH; Lin, CH; Lu, YS; Ono, M; Ueno, T; Naito, Y; Onishi, T; Lim, GH; Tan, SM; Lee, HB; Koh, J; Han, W; Im, SA; Tan, VKM; Phyu, N; Wong, FY; Tan, PH; Yap, YS
View PubMed
NAT MED 2024 10.1038/s41591-024-03060-0
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial
Mukohara, T; Park, YH; Sommerhalder, D; Yonemori, K; Hamilton, E; Kim, SB; Kim, JH; Iwata, H; Yamashita, T; Layman, RM; Mita, M; Clay, T; Chae, YS; Oakman, C; Yan, FT; Kim, GM; Im, SA; Lindeman, GJ; Rugo, HS; Liyanage, M; Saul, M; Le Corre, C; Skoura, A; Liu, L; Li, M; LoRusso, PM
View PubMed
JNCI-J NATL CANCER I 2024 10.1093/jnci/djae129
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
Dent, R; Cortés, J; Pusztai, L; Mcarthur, H; Kümmel, S; Bergh, J; Denkert, C; Park, YH; Hui, R; Harbeck, N; Takahashi, M; Untch, M; Fasching, PA; Cardoso, F; Haiderali, A; Jia, LY; Nguyen, AM; Pan, W; O'Shaughnessy, J; Schmid, P
View PubMed
BREAST CANCER-TOKYO 2024 10.1007/s12282-024-01600-7
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
Yamashita, T; Sohn, JH; Tokunaga, E; Niikura, N; Park, YH; Lee, KS; Chae, YS; Xu, BH; Wang, XJ; Im, SA; Li, W; Lu, YS; Aguilar, CO; Nishijima, S; Nishiyama, Y; Sugihara, M; Modi, S; Tsurutani, J
View PubMed
ESMO OPEN 2024 10.1016/j.esmoop.2024.102974
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer
Park, KH; Loibl, S; Sohn, J; Park, YH; Jiang, Z; Tadjoedin, H; Nag, S; Saji, S; Yusof, MM; Villegas, EMB; Lim, EH; Lu, YS; Ithimakin, S; Tseng, LM; Dejthevaporn, T; Chen, TWW; Lee, S; Galvez, C; Malwinder, S; Kogawa, T; Bajpai, J; Brahma, B; Wang, S; Curigliano, G; Yoshino, T; Kim, SB; Pentheroudakis, G; Im, SA; Andre, F; Ahn, JB; Harbeck, N
View PubMed
ANN ONCOL 2024 10.1016/j.annonc.2024.02.002
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 5
Pusztai, L; Denkert, C; O'Shaughnessy, J; Cortes, J; Dent, R; Mcarthur, H; Kümmel, S; Bergh, J; Park, YH; Hui, R; Harbeck, N; Takahashi, M; Untch, M; Fasching, PA; Cardoso, F; Zhu, Y; Pan, W; Tryfonidis, K; Schmid, P
View PubMed
BMC CANCER 2024 10.1186/s12885-024-12179-9
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
Kuemmel, S; Harper-Wynne, C; Park, YH; Franke, F; de Laurentiis, M; Schumacher-Wulf, E; Eiger, D; Heeson, S; Cardona, A; Özyilkan, O; Morales-Vàsquez, F; Metcalfe, C; Hafner, M; Restuccia, E; O'Shaughnessy, J
View PubMed
ESMO OPEN 2024 10.1016/j.esmoop.2024.102924
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
Hurvitz, SA; Kim, SB; Chung, WP; Im, SA; Park, YH; Hegg, R; Kim, MH; Tseng, LM; Petry, V; Chung, CF; Iwata, H; Hamilton, E; Curigliano, G; Xu, B; Egorov, A; Liu, Y; Cathcart, J; Bako, E; Tecson, K; Verma, S; Cortés, J
View PubMed
ANN ONCOL 2024 10.1016/j.annonc.2023.12.001
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
Saura, C; Modi, S; Krop, I; Park, YH; Kim, SB; Tamura, K; Iwata, H; Tsurutani, J; Sohn, J; Mathias, E; Liu, Y; Cathcart, J; Singh, J; Yamashita, T
View PubMed
BREAST CANCER-TOKYO 2024 10.1007/s12282-024-01559-5
Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile
Kang, DB; Park, S; Kim, HJ; Lee, JS; Han, JY; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Kim, JY; Nam, SJ; Cho, JH; Park, YH
View PubMed
BREAST CANCER RES 2024 10.1186/s13058-024-01768-y
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer
Park, J; Chang, ES; Kim, JY; Chelakkot, C; Sung, M; Song, JY; Jung, K; Lee, JH; Choi, JY; Kim, NY; Lee, H; Kang, MR; Kwon, MJ; Shin, YK; Park, YH; Choi, YL
View PubMed
THER ADV MED ONCOL 2024 10.1177/17588359231225029
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
Baek, SK; Jeong, JH; Jung, K; Ahn, HK; Kim, MH; Sohn, J; Park, IH; Ahn, JS; Lee, DW; Im, SA; Sim, SH; Lee, KS; Kim, JH; Shim, HJ; Chae, Y; Koh, SJ; Lee, H; Lee, J; Byun, JH; Seol, Y; Lee, EM; Jee, HJ; An, H; Park, EB; Suh, YJ; Lee, KE; Park, YH
View PubMed
EUR J CANCER 2024 10.1016/j.ejca.2023.113456
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
Lee, DW; Jung, KH; Lee, KH; Park, YH; Lee, KS; Sohn, J; Ahn, HK; Jeong, JH; Koh, SJ; Kim, JH; Kim, HJ; Lee, KE; Kim, HJ; Park, KH; Yang, YW; Lee, J; Won, HS; Kim, TY; Im, SA
View PubMed
CANCER RES TREAT 2024 10.4143/crt.2023.673
Impact of Social Support during Diagnosis and Treatment on Disease Progression in Young Patients with Breast Cancer: A Prospective Cohort Study
Kang, D; Park, S; Kim, HJ; Kim, SW; Lee, JE; Yu, J; Lee, SK; Kim, JY; Nam, SJ; Cho, J; Park, YH
View PubMed
BREAST 2023 10.1016/j.breast.2023.103594
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/ pertuzumab for HER2-positive breast cancer
Kim, N; Kim, JY; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Lee, JE; Nam, SJ; Kim, SW; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Park, YH; Kim, H
View PubMed
EUR J CANCER 2023 10.1016/j.ejca.2023.113386
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Kim, SH; Im, SA; Suh, KJ; Lee, KH; Kim, MH; Sohn, J; Park, YH; Kim, JY; Jeong, JH; Lee, KE; Choi, IS; Park, KH; Kim, HJ; Cho, EK; Park, SY; Kim, M; Kim, JH
View PubMed
BREAST CANCER RES TR 2023 10.1007/s10549-023-07165-x
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Balmana, J; Fasching, PA; Couch, FJ; Delaloge, S; Labidi-Galy, I; O'Shaughnessy, J; Park, YH; Eisen, AF; You, BN; Bourgeois, H; Goncalves, A; Kemp, Z; Swampillai, A; Jankowski, T; Sohn, JH; Poddubskaya, E; Mukhametshina, G; Aksoy, S; Timcheva, CV; Park-Simon, TW; Anton-Torres, A; John, E; Baria, K; Gibson, I; Gelmon, KA; Koynova, T; Popov, V; Timcheva, C; Tomova, A; Eisen, A; Gelmon, K; Lemieux, J; Augereau, P; Bazan, F; Becuwe, C; Bourgeois, H; Chakiba, C; Chehimi, M; Cheneau, C; Dalenc, F; de Guillebon, E; Rouge, TD; Frenel, JS; Goncalves, A; Grenier, J; Hardy-Bessard, AC; Lamy, R; Levy, C; Lortholary, A; Mailliez, A; Medioni, J; Patsouris, A; Spaeth, D; Teixeira, L; Tennevet, I; Venat-Bouvet, L; Villanueva, C; You, BN; Ettl, J; Fasching, P; Gerber, B; Hanusch, CA; Hoffmann, O; Park-Simon, TW; Malter, W; Reinisch, M; Tio, J; Wimberger, P; Boer, K; Dank, M; Ballestrero, A; Bianchini, G; Biganzoli, L; Bordonaro, R; Cognetti, F; Cortesi, E; De Laurentiis, M; De Placido, S; Gianni, L; Gu
View PubMed
ACAD RADIOL 2023 10.1016/j.acra.2023.03.008
Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications
Oh, J; Han, BK; Ko, EY; Ko, ES; Choi, JS; Kim, H; Park, YH; Kim, JY
View PubMed
INT J MOL SCI 2023 10.3390/ijms242115576
A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Jung, HH; Kim, JY; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
View PubMed
JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.42107
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Takahashi, M; Cortés, J; Dent, R; Pusztai, L; Mcarthur, H; Kümmel, S; Denkert, C; Park, YH; Im, SA; Ahn, JH; Mukai, H; Huang, CS; Chen, SC; Kim, MH; Jia, LY; Li, XT; Tryfonidis, K; Karantza, V; Iwata, H; Schmid, P
View PubMed
CANCERS 2023 10.3390/cancers15194720
Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer
Shin, J; Kim, JY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, W; Park, YH; Ahn, JS; Im, YH
View PubMed
RADIAT ONCOL 2023 10.1186/s13014-023-02357-7
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
Kim, N; Kim, H; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Park, YH; Kim, JY
View PubMed
MOL CANCER THER 2023 10.1158/1535-7163.MCT-23-0101
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Meric-Bernstam, F; Calvo, E; Lee, KS; Moreno, V; Park, YH; Rha, SY; Chalasani, P; Zhong, W; Zhou, L; Pirie-Shepherd, S; Leung, ACF; Curigliano, G
View PubMed
LANCET ONCOL 2023
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
Hurvitz, SA; Bardia, A; Quiroga, V; Park, YH; Blancas, I; Alonso-Romero, JL; Vasiliev, A; Adamchuk, H; Salgado, M; Yardley, DA; Berzoy, O; Zamora-Auñán, P; Chan, DV; Spera, G; Xue, CR; Ferreira, E; Crnjevic, TB; Pérez-Moreno, PD; López-Valverde, V; Steinseifer, J; Fernando, TM; Moore, HM; coopERA Breast Cancer study grp
View PubMed
DRUG SAFETY 2023 10.1007/s40264-023-01328-x
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Chiu, JWY; Lee, SC; Ho, JCM; Park, YH; Chao, TC; Kim, SB; Lim, E; Lin, CH; Loi, S; Low, SY; Teo, LL; Yeo, WN; Dent, R
View PubMed
THER ADV MED ONCOL 2023 10.1177/17588359231189421
Pretreatment endocrine symptoms and recurrence-free survival among young premenopausal patients with breast cancer: a prospective cohort study
Kang, DB; Cho, JH; Park, S; Kim, HJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Kim, JY; Nam, SJ; Park, YH
View PubMed
CANCER RES TREAT 2023 10.4143/crt.2022.987
Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
Moon, YW; Kim, SK; Lee, KS; Lee, MH; Park, YH; Park, KH; Kim, GM; Lim, S; Lee, SA; Choi, JD; Baek, E; Han, H; Baek, S; Im, SA
View PubMed
EXP MOL MED 2023 10.1038/s12276-023-01030-z
Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
Kim, JY; Park, S; Cho, EY; Lee, JE; Jung, HH; Chae, BJ; Kim, SW; Nam, SJ; Cho, SY; Park, YH; Ahn, JS; Lee, S; Im, YH
View PubMed
CANCERS 2023 10.3390/cancers15133431
Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Kim, JY; Shin, J; Ahn, JS; Park, YH; Im, YH
View PubMed
GENOME MED 2023 10.1186/s13073-023-01201-7
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
Park, YH; Im, SA; Park, K; Wen, J; Lee, KH; Choi, YL; Lee, WC; Min, A; Bonato, V; Park, S; Ram, S; Lee, DW; Kim, JY; Lee, SK; Lee, WW; Lee, J; Kim, M; Kim, HS; Weinrich, SL; Ryu, HS; Kim, TY; Dann, S; Kim, YJ; Fernandez, DR; Koh, J; Wang, SG; Park, SY; Deng, SB; Powell, E; Ravi, RK; Bienkowska, J; Rejto, PA; Park, WY; Kan, ZY
View PubMed
CANCERS 2023 10.3390/cancers15133435
Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study
Kwak, Y; Jang, SY; Choi, JY; Lee, H; Shin, DS; Park, YH; Kim, JY; Ahn, JS; Chae, BJ; Yu, J; Lee, JE; Kim, SW; Nam, SJ; Ryu, JM
View PubMed
ONCOLOGIST 2023 10.1093/oncolo/oyad156
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer
Lee, HB; Lee, KH; Song, SH; Kim, K; Kim, HK; Moon, HG; Han, WS; Lee, DW; Im, SA; Jang, BS; Kim, YB; Yu, JH; Kim, JH; Park, YH; Shin, KH; Chang, JH
View PubMed
SCI REP-UK 2023 10.1038/s41598-023-35925-8
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2+metastatic breast cancer
Lee, K; Lee, J; Choi, J; Sim, SH; Kim, JE; Kim, MH; Park, YH; Kim, JH; Koh, SJ; Park, KH; Kang, MJ; Ahn, MS; Lee, KE; Kim, HJ; Ahn, HK; Kim, HJ; Park, KU; Park, IH
View PubMed
NEW ENGL J MED 2023 10.1056/NEJMoa2214131
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
Turner, NC; Oliveira, M; Howell, SJ; Dalenc, F; Cortes, J; Moreno, HLG; Hu, XC; Jhaveri, K; Krivorotko, P; Loibl, S; Murillo, SM; Okera, M; Park, YH; Sohn, J; Toi, M; Tokunaga, E; Yousef, S; Zhukova, L; de Bruin, EC; Grinsted, L; Schiavon, G; Foxley, A; Rugo, HS
View PubMed
ESMO OPEN 2023 10.1016/j.esmoop.2023.101541
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Im, SA; Gennari, A; Park, YH; Kim, JH; Jiang, ZF; Gupta, S; Fadjari, TH; Tamura, K; Mastura, MY; Abesamis-Tiambeng, MLT; Lim, EH; Lin, CH; Sookprasert, A; Parinyanitikul, N; Tseng, LM; Lee, SC; Caguioa, P; Singh, M; Naito, Y; Hukom, RA; Smruti, BK; Wang, SS; Kim, SB; Lee, KH; Ahn, HK; Peters, S; Kim, TW; Yoshino, T; Pentheroudakis, G; Curigliano, G; Harbeck, N
View PubMed
NAT CANCER 2023 10.1038/s43018-023-00572-5
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer
Sung, C; An, J; Lee, S; Park, J; Lee, KS; Kim, I; Han, JY; Park, YH; Kim, JH; Kang, EJ; Hong, MH; Kim, TY; Lee, JC; Lee, JL; Yoon, S; Choi, CM; Lee, DH; Yoo, C; Kim, SW; Jeong, JH; Seo, S; Kim, SY; Kong, SY; Choi, JK; Park, SR
View PubMed
CANCERS 2023 10.3390/cancers15092646
Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer
Lee, H; Choi, JY; Park, YH; Lee, JE; Kim, SW; Nam, SJ; Cho, YS
View PubMed
LANCET 2023 10.1016/S0140-6736(23)00725-0
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial
Andre, F; Park, YH; Kim, SB; Takano, T; Im, SA; Borges, G; Lima, JP; Aksoy, S; Gregori, JG; De Laurentiis, M; Bianchini, G; Roylance, R; Miyoshi, Y; Armstrong, A; Sinha, R; Borrego, MR; Lim, E; Ettl, J; Yerushalmi, R; Zagouri, F; Duhoux, FP; Fehm, T; Gambhire, D; Cathcart, J; Wu, C; Chu, CA; Egorov, A; Krop, I
View PubMed
BREAST CANCER RES TR 2023 10.1007/s10549-023-06936-w
Comparison of initial and sequential salvage brain-directed treatment in patients with 1-4 vs. 5-10 brain metastases from breast cancer (KROG 16-12)
Kim, JS; Kim, K; Jung, W; Shin, KH; Im, SA; Kim, HJ; Kim, YB; Chang, JS; Kim, JH; Choi, DH; Park, YH; Kim, DY; Kim, TH; Choi, BO; Lee, SW; Kim, S; Kwon, J; Kang, KM; Chung, WK; Kim, KS; Yoon, WS; Kim, JH; Cha, J; Oh, YK; Kim, IA
View PubMed
J BREAST CANCER 2023 10.4048/jbc.2023.26.e17
Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level
Ryu, JM; Kang, DB; Cho, JH; Lee, JE; Kim, SW; Nam, SJ; Lee, SK; Kim, YJ; Im, YH; Ahn, JS; Park, YH; Kim, JY; Lee, HYJ; Kang, MR; Yu, JH
View PubMed
CANCER RES TREAT 2023 10.4143/crt.2022.1360
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
Lee, DW; Keam, B; Lee, KS; Ahn, JH; Sohn, J; Ahn, JS; Lee, MH; Kim, JH; Lee, KE; Kim, HJ; Kim, SY; Park, YH; Ock, CY; Lee, KH; Han, SW; Kim, SB; Im, YH; Chung, HC; Oh, D; Im, SA
View PubMed
FUTURE ONCOL 2023 10.2217/fon-2022-1196
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment
Turner, N; Huang-Bartlett, C; Kalinsky, K; Cristofanilli, M; Bianchini, G; Chia, SP; Iwata, H; Janni, W; Ma, CX; Mayer, EL; Park, YH; Fox, S; Liu, XC; McClain, S; Bidard, FC
View PubMed
J MED INTERNET RES 2023 10.2196/43359
Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study
Kim, MJ; Kim, HJ; Kang, DB; Ahn, HK; Shin, SY; Park, S; Cho, JH; Park, YH
View PubMed
FRONT ONCOL 2023 10.3389/fonc.2023.1146934
Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
Kim, JY; Kim, J; Cho, EY; Park, YH; Ahn, JS; Kim, KM; Im, YH
View PubMed
BREAST CANCER-TOKYO 2023 10.1007/s12282-023-01436-7
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
Imoto, S; Wang, K; Bi, XW; Liu, GY; Im, YH; Im, SA; Sim, SH; Ueno, T; Futamura, M; Toi, M; Fujiwara, Y; Ahn, SG; Lee, JE; Park, YH; Takao, S; Oba, MS; Kitagawa, Y; Nishiyama, M
View PubMed
FRONT ONCOL 2023 10.3389/fonc.2023.1109694
Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians
Baek, SY; Lee, KH; Kim, SB; Gomez, H; Vidaurre, T; Park, YH; Ahn, HK; Kim, YS; Park, IH; Ahn, SG; Lee, JY; Jeong, JH; Kim, S; Kim, HJ
View PubMed
CANCER DISCOV 2022 10.1158/2159-8290.CD-22-0837
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Jerusalem, G; Park, YH; Yamashita, T; Hurvitz, SA; Modi, S; Andre, F; Krop, IE; Farre, XG; You, B; Saura, C; Kim, SB; Osborne, CR; Murthy, RK; Gianni, L; Takano, T; Liu, YL; Cathcart, J; Lee, C; Perrin, C
View PubMed
THER ADV MED ONCOL 2022 10.1177/17588359221132628
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group
Han, HS; Lee, KE; Suh, YJ; Jee, HJ; Kim, BJ; Kim, HS; Lee, KW; Ryu, MH; Baek, SK; Park, IH; Ahn, HK; Jeong, JH; Kim, MH; Lee, DH; Kim, S; Moon, H; Son, S; Byun, JH; Kim, DS; An, H; Park, YH; Zang, DY
View PubMed
FUTURE ONCOL 2022 10.2217/fon-2022-0485
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer
Hurvitz, SA; Bachelot, T; Bianchini, G; Harbeck, N; Loi, S; Park, YH; Prat, A; Gilham, L; Boulet, T; Gochitashvili, N; Monturus, E; Lambertini, C; Nyawira, B; Knott, A; Restuccia, E; Schmid, P
View PubMed
ANN ONCOL 2022 10.1016/j.annonc.2022.09.159
Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Geyer, CE; Garber, JE; Gelber, RD; Yothers, G; Taboada, M; Ross, L; Rastogi, P; Cui, K; Arahmani, A; Aktan, G; Armstrong, AC; Arnedos, M; Balmana, J; Bergh, J; Bliss, J; Delaloge, S; Domchek, SM; Eisen, A; Elsafy, F; Fein, LE; Fielding, A; Ford, JM; Friedman, S; Gelmon, KA; Gianni, L; Gnant, M; Hollingsworth, SJ; Im, SA; Jager, A; Lakhani, SR; Janni, W; Linderholm, B; Liu, TW; Loman, N; Korde, L; Loibl, S; Lucas, PC; Marme, F; de Duenas, EM; McConnell, R; Phillips, KA; Piccart, M; Rossi, G; Schmutzler, R; Senkus, E; Shao, Z; Sharma, P; Singer, CF; Spanic, T; Stickeler, E; Toi, M; Traina, TA; Viale, G; Zoppoli, G; Park, YH; Yerushalmi, R; Yang, H; Pang, D; Jung, KH; Mailliez, A; Fan, Z; Tennevet, I; Zhang, J; Nagy, T; Sonke, GS; Sun, Q; Parton, M; Colleoni, MA; Schmidt, M; Brufsky, AM; Razaq, W; Kaufman, B; Cameron, D; Campbell, C; Tutt, ANJ; Johannsson, OT
View PubMed
CANCER RES TREAT 2022 10.4143/crt.2021.901
Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/ Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
Kim, JY; Nam, SJ; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Ahn, JS; Im, YH; Kim, SW; Park, YH
View PubMed
CANCER RES TREAT 2022 10.4143/crt.2021.1083
The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
Kim, JS; Kim, K; Jung, W; Shin, KH; Im, SA; Kim, HJ; Kim, YB; Chang, JS; Kim, JH; Choi, DH; Park, YH; Kim, DY; Kim, TH; Choi, BO; Lee, SW; Kim, S; Kwon, J; Kang, KM; Chung, WK; Kim, KS; Nam, JH; Yoon, WS; Kim, JH; Cha, J; Oh, YK; Kim, IA
View PubMed
CANCERS 2022 10.3390/cancers14194839
Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort
Jo, H; Park, S; Kim, HR; Kim, H; Hong, J; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Oh, SY; Choi, SJ; Kim, JY; Ahn, JS; Im, YH; Nam, EM; Nam, SJ; Park, YH
View PubMed
CANCER RES TREAT 2022 10.4143/crt.2021.1103
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Lee, YP; Lee, MS; Kim, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
View PubMed
J AM ACAD DERMATOL 2022 10.1016/j.jaad.2021.10.047
Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial
Kang, D; Kim, N; Im, YH; Park, YH; Kim, JY; Park, H; Kim, E; Zhao, D; Guallar, E; Ahn, JS; Cho, J
View PubMed
BREAST 2022 10.1016/j.breast.2022.08.002
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
Sim, SH; Kim, JE; Kim, MH; Park, YH; Kim, JH; Suh, KJ; Koh, SJ; Park, KH; Kang, MJ; Ahn, MS; Lee, KE; Kim, HJ; Ahn, HK; Kim, HJ; Park, KU; Byun, JH; Park, JH; Lee, GW; Lee, KS; Sohn, J; Jung, KH; Park, IH
View PubMed
JAMA ONCOL 2022 10.1001/jamaoncol.2022.2310
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial
Ahn, HK; Sim, SH; Suh, KJ; Kim, MH; Jeong, JH; Kim, JY; Lee, DW; Ahn, JH; Chae, H; Lee, KH; Kim, JH; Lee, KS; Sohn, JH; Choi, YL; Im, SA; Jung, KH; Park, YH
View PubMed
CANCER GENET-NY 2022 10.1016/j.cancergen.2022.05.042
Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
Kwon, WK; Jang, HJ; Lee, JE; Park, YH; Ryu, JM; Yu, J; Jang, JH; Kim, JW
View PubMed
THER ADV MED ONCOL 2022 10.1177/17588359221106564
Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
Hong, J; Park, YH
View PubMed
NEW ENGL J MED 2022 10.1056/NEJMoa2203690
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S; Jacot, W; Yamashita, T; Sohn, J; Vidal, M; Tokunaga, E; Tsurutani, J; Ueno, NT; Prat, A; Chae, YS; Lee, KS; Niikura, N; Park, YH; Xu, BH; Wang, XJ; Gil-Gil, M; Li, W; Pierga, JY; Im, SA; Moore, HCF; Rugo, HS; Yerushalmi, R; Zagouri, F; Gombos, A; Kim, SB; Liu, Q; Luo, T; Saura, C; Schmid, P; Sun, T; Gambhire, D; Yung, LT; Wang, YB; Singh, J; Vitazka, P; Meinhardt, G; Harbeck, N; Cameron, DA
View PubMed
FRONT ONCOL 2022 10.3389/fonc.2022.903372
Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
Kim, JY; Oh, JM; Lee, SK; Yu, J; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kim, K; Im, YH
View PubMed
SCI REP-UK 2022 10.1038/s41598-022-09542-w
Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study
Kang, D; Kang, M; Hong, YS; Park, J; Lee, J; Seo, HJ; Kim, DW; Ahn, JS; Park, YH; Lee, SK; Shin, DW; Guallar, E; Cho, J
View PubMed
NEW ENGL J MED 2022 10.1056/NEJMoa2115022
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortes, J; Kim, SB; Chung, WP; Im, SA; Park, YH; Hegg, R; Kim, MH; Tseng, LM; Petry, V; Chung, CF; Iwata, H; Hamilton, E; Curigliano, G; Xu, B; Huang, CS; Kim, JH; Chiu, JWY; Pedrini, JL; Lee, C; Liu, Y; Cathcart, J; Bako, E; Verma, S; Hurvitz, SA
View PubMed
BMC MED 2022 10.1186/s12916-022-02284-6
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
Tan, RSYC; Ong, WS; Lee, KH; Lim, AH; Park, S; Park, YH; Lin, CH; Lu, YS; Ono, M; Ueno, T; Naito, Y; Onishi, T; Lim, GH; Tan, SM; Lee, HB; Ryu, HS; Han, W; Tan, VKM; Wong, FY; Im, SA; Tan, PH; Chan, JY; Yap, YS
View PubMed
BMC MED 2022 10.1186/s12916-022-02260-0
The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology
Hirko, KA; Rocque, G; Reasor, E; Taye, A; Daly, A; Cutress, RI; Copson, ER; Lee, DW; Lee, KH; Im, SA; Park, YH
View PubMed
BREAST 2022 10.1016/j.breast.2022.01.014
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
Lee, S; Park, K; Kim, GM; Jung, KH; Kang, SY; Park, IH; Kim, JH; Ahn, HK; Park, WY; Im, SA; Park, YH
View PubMed
NEW ENGL J MED 2022 10.1056/NEJMoa2112651
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P; Cortes, J; Dent, R; Pusztai, L; McArthur, H; Kummel, S; Bergh, J; Denkert, C; Park, YH; Hui, R; Harbeck, N; Takahashi, M; Untch, M; Fasching, PA; Cardoso, F; Andersen, J; Patt, D; Danso, M; Ferreira, M; Mouret-Reynier, MA; Im, SA; Ahn, JH; Gion, M; Baron-Hay, S; Boileau, JF; Ding, Y; Tryfonidis, K; Aktan, G; Karantza, V; O'Shaughnessy, J
View PubMed
BLOOD CANCER J 2021 10.1038/s41408-021-00595-0
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study
Kang, D; Yoon, SE; Shin, D; Lee, J; Hong, YS; Lee, SK; Lee, JE; Park, YH; Ahn, JS; Guallar, E; Kim, WS; Lee, J; Kim, SJ; Cho, J
View PubMed
CANCERS 2021 10.3390/cancers13225835
Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
Kim, H; Kim, HJ; Kim, H; Kim, HR; Jo, H; Hong, J; Kim, R; Kim, JY; Ahn, JS; Im, YH; Lee, SK; Kim, H; Shin, SY; Park, YH
View PubMed
BREAST 2021 10.1016/j.breast.2021.11.005
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
Kim, JS; Kim, K; Jung, W; Shin, KH; Im, SA; Kim, YB; Chang, JS; Choi, DH; Kim, H; Park, YH; Kim, DY; Kim, TH; Kwon, J; Kang, KM; Chung, WK; Kim, KS; Kim, IA
View PubMed
CANCERS 2021 10.3390/cancers13215260
Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Jung, HH; Kim, JY; Cho, EY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
View PubMed
FUTURE ONCOL 2021 10.2217/fon-2021-0550
Trastuzumab deruxtecan for HER2+advanced breast cancer
Lee, J; Park, YH
View PubMed
FRONT ONCOL 2021 10.3389/fonc.2021.759150
Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
Kim, JY; Oh, JM; Park, YH; Ahn, JS; Im, YH
View PubMed
BREAST CANCER RES TR 2021 10.1007/s10549-021-06309-1
Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea
Park, YH; Karantza, V; Calhoun, SR; Park, S; Lee, S; Kim, JY; Yu, JH; Kim, SW; Lee, JE; Nam, SJ; Aktan, G; Marsico, M
View PubMed
TARGET ONCOL 2021 10.1007/s11523-021-00838-x
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
Lu, YS; Yeo, WN; Yap, YS; Park, YH; Tamura, K; Li, HP; Cheng, R
View PubMed
ESMO OPEN 2021 10.1016/j.esmoop.2021.100236
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
Cho, EH; Kim, JY; Im, SA; Jung, KH; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Jang, JH; Ahn, JH; Park, MS; Lee, SY; Park, YH
View PubMed
CLIN BREAST CANCER 2021 10.1016/j.clbc.2020.12.013
Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Kim, HK; Lee, HS; Heo, MH; Kim, JY; Ahn, JS; Im, YH; Lee, JI; Park, YH
View PubMed
BREAST CANCER RES TR 2021 10.1007/s10549-021-06310-8
Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer
Kim, JY; Jeon, E; Kwon, S; Jung, H; Joo, S; Park, Y; Lee, SK; Lee, JE; Nam, SJ; Cho, EY; Park, YH; Ahn, JS; Im, YH
View PubMed
INVEST NEW DRUG 2021 10.1007/s10637-021-01078-6
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
Keam, B; Ock, CY; Kim, TM; Oh, D; Kang, WK; Park, YH; Lee, J; Lee, JH; Ahn, YH; Kim, HJ; Chang, SK; Park, J; Choi, JY; Song, YJ; Park, YS
View PubMed
CANCER RES TREAT 2021 10.4143/crt.2020.1246
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
Lee, J; Im, SA; Kim, GM; Jung, KH; Kang, SY; Park, IH; Kim, JH; Ahn, HK; Park, YH
View PubMed
ONCOLOGIST 2021 10.1002/onco.13833
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3
Rugo1, HS; Cristofanilli, M; Loibl, S; Harbeck, N; DeMichele, A; Iwata, H; Park, YH; Brufsky, A; Theall, KP; Huang, X; McRoy, L; Bananis, E; Turner, NC
CYTOKINE 2021 10.1016/j.cyto.2021.155487
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)
Kim1, JW; Lee, S; Kim, HS; Choi, YJ; Yoo, J; Park, KU; Kang, SY; Park, YH; Jung, KH; Ahn, JH; Oh, HS; Choi, IS; Kim, HJ; Lee, KH; Lee, S; Seo, JH; Park, IH; Lee, KE; Kim, HY; Park, KH
FRONT ONCOL 2021 10.3389/fonc.2021.596364
Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry
Kim1, JY; Lee, YS; Yu, J; Park, Y; Lee, SK; Lee, M; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kang, M; Im, YH
LANCET ONCOL 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Rugo1, HS; Lerebours, F; Ciruelos, E; Drullinsky, P; Ruiz-Borrego, M; Neven, P; Park, YH; Prat, A; Bachelot, T; Juric, D; Turner, N; Sophos, N; Zarate, JP; Arce, C; Shen, YM; Turner, S; Kanakamedala, H; Hsu, WC; Chia, S
FRONT ONCOL 2021 10.3389/fonc.2021.653243
The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
Lee1, K; Sim, SH; Kang, EJ; Seo, JH; Chae, H; Lee, KS; Kim, JY; Ahn, JS; Im, YH; Park, S; Park, YH; Park, IH
DIAGNOSTICS 2021 10.3390/diagnostics11020370
Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
Hong1, J; Lee, J; Kwon, M; Kim, JY; Kim, JW; Ahn, JS; Im, YH; Park, YH
CLIN CANCER RES 2021 10.1158/1078-0432.CCR-20-1008
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Lu1, YS; Lee, KS; Chao, TY; Tseng, LM; Chitapanarux, I; Chen, SC; Liu, CT; Sohn, J; Kim, JH; Chang, YC; Yang, YS; Shotelersuk, K; Jung, KH; Valenti, R; Slader, C; Gao, M; Park, YH
BREAST CANCER RES TREAT 2021 10.1007/s10549-020-06043-0
New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)
Kim1, JS; Kim, K; Jung, W; Shin, KH; Im, SA; Kim, HJ; Kim, YB; Chang, JS; Kim, JH; Choi, DH; Park, YH; Kim, DY; Kim, TH; Choi, BO; Lee, SW; Kim, S; Kwon, J; Kang, KM; Chung, WK; Kim, KS; Yoon, WS; Kim, JH; Cha, J; Oh, YK; Kim, IA
NAT COMMUN 2020 10.1038/s41467-020-19933-0
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Park1, YH; Lal, S; Lee, JE; Choi, YL; Wen, J; Ram, S; Ding, Y; Lee, SH; Powell, E; Lee, SK; Yu, JH; Ching, KA; Nam, JY; Kim, SW; Nam, SJ; Kim, JY; Cho, SY; Park, S; Kim, J; Hwang, S; Kim, YJ; Bonato, V; Fernandez, D; Deng, S; Wang, S; Shin, H; Kang, ES; Park, WY; Rejto, PA; Bienkowska, J; Kan, Z
CANCERS 2020 10.3390/cancers12113265
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
Lee1, S; Im, SA; Kim, GM; Jung, KH; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Park, YH
J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
SCI REP-UK 2020 10.1038/s41598-020-75620-6
The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer
Lee1, SY; Kim, EK; Kim, JY; Park, TK; Choi, SH; Im, YH; Kim, MY; Park, YH; Kim, DK
LANCET ONCOL 2020 10.1016/S1470-2045(20)30447-2
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3) a randomised, double-blind, placebo-controlled, phase 3 trial
Dieras1, V; Han, HS; Kaufman, B; Wildiers, H; Friedlander, M; Ayoub, JP; Puhalla, SL; Bondarenko, I; Campone, M; Jakobsen, EH; Jalving, M; Oprean, C; Palacova, M; Park, YH; Shparyk, Y; Yanez, E; Khandelwal, N; Kundu, MG; Dudley, M; Ratajczak, CK; Maag, D; Arun, BK
LANCET ONCOL 2020 10.1016/S1470-2045(20)30324-7
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) an open-label, multicentre, phase 1/2, basket study
Domchek1, SM; Postel-Vinay, S; Im, SA; Park, YH; Delord, JP; Italiano, A; Alexandre, J; You, B; Bastian, S; Krebs, MG; Wang, D; Waqar, SN; Lanasa, M; Rhee, J; Gao, HY; Rocher-Ros, V; Jones, EV; Gulati, S; Coenen-Stass, A; Kozarewa, I; Lai, ZW; Angell, HK; Opincar, L; Herbolsheimer, P; Kaufman, B
MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer
Park1, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH
BREAST CANCER RES TR 2020 10.1007/s10549-020-05874-1
Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer
Kim1, JY; Jung, HH; Sohn, I; Woo, SY; Cho, H; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
BREAST CANCER RES TR 2020 10.1007/s10549-020-05891-0
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Kim1, JY; Park, K; Im, SA; Jung, KH; Sohn, J; Lee, KS; Kim, JH; Yang, Y; Park, YH
ANN ONCOL 2020 10.1016/j.annonc.2020.01.072
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Schmid1, P; Salgado, R; Park, YH; Munoz-Couselo, E; Kim, SB; Sohn, J; Im, SA; Foukakis, T; Kuemmel, S; Dent, R; Yin, L; Wang, A; Tryfonidis, K; Karantza, V; Cortes, J; Loi, S
CANCERS 2020 10.3390/cancers12051306
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience
Hur1, JY; Kim, JY; Ahn, JS; Im, YH; Lee, J; Kwon, M; Park, YH
ANTICANCER RES 2020 10.21873/anticanres.14271
Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology
Park1, S; Cho, EY; Oh, YL; Park, YH; Kim, HS
SUPPORT CARE CANCER 2020 10.1007/s00520-019-04982-z
Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
Kang1, D; Kim, IR; Park, YH; Im, YH; Zhao, D; Guallar, E; Ahn, JS; Cho, J
ANN ONCOL 2020 10.1016/j.annonc.2020.01.008
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Park1, YH; Senkus-Konefka, E; Im, SA; Pentheroudakis, G; Saji, S; Gupta, S; Iwata, H; Mastura, MY; Dent, R; Lu, YS; Yin, Y; Smruti, BK; Toyama, T; Malwinder, S; Lee, SC; Tseng, LM; Kim, JH; Kim, TY; Suh, KJ; Cardoso, F; Yoshino, T; Douillard, JY
NEW ENGL J MED 2020 10.1056/NEJMoa1910549
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid1, P; Cortes, J; Pusztai, L; McArthur, H; Kummel, S; Bergh, J; Denkert, C; Park, YH; Hui, R; Harbeck, N; Takahashi, M; Foukakis, T; Fasching, PA; Cardoso, F; Untch, M; Jia, L; Karantza, V; Zhao, J; Aktan, G; Dent, R; O'Shaughnessy, J
NEW ENGL J MED 2020 10.1056/NEJMoa1914510
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Modi1, S; Saura, C; Yamashita, T; Park, YH; Kim, SB; Tamura, K; Andre, F; Iwata, H; Ito, Y; Tsurutani, J; Sohn, J; Denduluri, N; Perrin, C; Aogi, K; Tokunaga, E; Im, SA; Lee, KS; Hurvitz, SA; Cortes, J; Lee, CL; Chen, SQ; Zhang, L; Shahidi, J; Yver, A; Krop, I
J CLIN ONCOL 2020 10.1200/JCO.19.00368
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Schmid1, P; Abraham, J; Chan, S; Wheatley, D; Brunt, AM; Nemsadze, G; Baird, RD; Park, YH; Hall, PS; Perren, T; Stein, RC; Mangel, L; Ferrero, JM; Phillips, M; Conibear, J; Cortes, J; Foxley, A; de Bruin, EC; McEwen, R; Stetson, D; Dougherty, B; Sarker, SJ; Prendergast, A; McLaughlin-Callan, M; Burgess, M; Lawrence, C; Cartwright, H; Mousa, K; Turner, NC
BREAST 2020 10.1016/j.breast.2019.10.007
Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12)
Kim1, JS; Kim, K; Jung, W; Shin, KH; Im, SA; Kim, HJ; Kim, YB; Chang, JS; Choi, DH; Park, YH; Kim, DY; Kim, TH; Choi, BO; Lee, SW; Kim, S; Kwon, J; Kang, KM; Chung, WK; Kim, KS; Nam, JH; Yoon, WS; Kim, JH; Cha, J; Oh, YK; Kim, IA
BRIT J CANCER 2019 10.1038/s41416-019-0618-z
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
Sim1, SH; Park, IH; Jung, KH; Kim, SB; Ahn, JH; Lee, KH; Im, SA; Im, YH; Park, YH; Sohn, J; Kim, YJ; Lee, S; Kim, HJ; Chae, YS; Park, KH; Nam, BH; Lee, KS; Ro, J
LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA
BREAST CANCER RES TR 2019 10.1007/s10549-019-05400-y
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
Kim1, JY; Lee, E; Park, K; Im, SA; Sohn, J; Lee, KS; Chae, YS; Kim, JH; Kim, TY; Jung, KH; Park, YH
BREAST CANCER RES TR 2019 10.1007/s10549-019-05318-5
Treating HR+/HER2-breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
Yeo1, W; Ueno, T; Lin, CH; Liu, Q; Lee, KH; Leung, R; Naito, Y; Park, YH; Im, SA; Li, HP; Yap, YS; Lu, YS
JAMA Oncol 2019 10.1001/jamaoncol.2019.0620
Insights Into Breast Cancer in the East vs the West: A Review
Yap1, YS; Lu, YS; Tamura, K; Lee, JE; Ko, EY; Park, YH; Cao, AY; Lin, CH; Toi, M; Wu, J; Lee, SC
KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
INT J CANCER 2019 10.1002/ijc.32188
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
Kim1, JY; Lee, E; Park, K; Jung, HH; Park, WY; Lee, KH; Sohn, J; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Im, SA; Park, YH
CANCER COMMUN 2019 10.1186/s40880-019-0375-7
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Kim1, JY; Park, S; Im, SA; Kim, SB; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH; Park, YH
CANCER RES TREAT 2019 10.4143/crt.2018.262
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF
CANCER RES TREAT 2019 10.4143/crt.2018.342
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH
SCI REP-UK 2019 10.1038/s41598-019-41098-0
Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator
Oh1, BY; Shin, HT; Yun, JW; Kim, KT; Kim, J; Bae, JS; Cho, YB; Lee, WY; Yun, SH; Park, YA; Park, YH; Im, YH; Lee, J; Joung, JG; Kim, HC; Park, WY
ONCOLOGIST 2019 10.1634/theoncologist.2018-0184
Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Kang1, D; Kim, IR; Choi, EK; Im, YH; Park, YH; Ahn, JS; Lee, JE; Nam, SJ; Lee, HK; Park, JH; Lee, DY; Lacouture, ME; Guallar, E; Cho, J
BRIT J CANCER 2019 10.1038/s41416-019-0391-z
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
Fujiwara1, Y; Mukai, H; Saeki, T; Ro, J; Lin, YC; Nagai, SE; Lee, KS; Watanabe, J; Ohtani, S; Kim, SB; Kuroi, K; Tsugawa, K; Tokuda, Y; Iwata, H; Park, YH; Yang, YS; Nambu, Y
ONCOL LETT 2019 10.3892/ol.2018.9754
Clinical features and prognosis of breast cancer with gastric metastasis
Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH
HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3
The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans
Kim1, H; Choi, DH; Park, W; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Jung, BY
BREAST CANCER RES TR 2019 10.1007/s10549-018-5015-4
Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea
Ryu1, JM; Choi, HJ; Kim, I; Nam, SJ; Kim, SW; Yu, J; Lee, SK; Choi, DH; Park, YH; Kim, JW; Seo, JS; Park, JH; Lee, JE; Kim, SW
CANCER RES TREAT 2019 10.4143/crt.2017.562
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
Park1, IH; Im, SA; Jung, KH; Sohn, JH; Park, YH; Lee, KS; Sim, SH; Park, KH; Kim, JH; Nam, BH; Kim, HJ; Kim, TY; Lee, KH; Kim, SB; Ahn, JH; Lee, S; Ro, J
BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
Hwang1, HW; Jung, H; Hyeon, J; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Choi, M; Cho, SY; Cho, EY
BMC CANCER 2019 10.1186/s12885-018-5258-9
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH
J BREAST CANC 2018 10.4048/jbc.2018.21.e48
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
Seo1, Y; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Cho, SY; Cho, EY
INT J CANCER 2018 10.1002/ijc.31651
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Park1, YH; Lee, KH; Sohn, JH; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Ahn, JS; Kim, TY; Kim, GM; Park, IH; Kim, SB; Kim, SH; Han, HS; Im, YH; Ahn, JH; Kim, JY; Kang, J; Im, SA
EUR J CANCER 2018 10.1016/j.ejca.2018.08.004
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH
BREAST CANCER RES TR 2018 10.1007/s10549-018-4863-2
Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy
Lee1, DY; Park, YH; Lee, JE; Choi, D
CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010
Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment
Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S
BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
J BREAST CANC 2018 10.4048/jbc.2018.21.2.206
Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?
Cho1, WK; Park, W; Choi, DH; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY
Oncoimmunology 2018 10.1080/2162402X.2018.1466768
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
Park1, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH
NAT COMMUN 2018 10.1038/s41467-018-04129-4
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan1, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH
J BREAST CANC 2018 10.4048/jbc.2018.21.1.91
Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy
Park1, JH; Lee, SK; Lee, JE; Kim, SW; Nam, SJ; Kim, JY; Ahn, JS; Park, W; Yu, J; Park, YH
TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.002
Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast
Kim1, JY; Yu, JH; Nam, SJ; Kim, SW; Lee, SK; Park, WY; Noh, DY; Nam, DH; Park, YH; Han, W; Lee, JE
PHARMACOGENOMICS 2017 10.2217/pgs-2017-0044
The nuclear factor-kappa B pathway and response to treatment in breast cancer
Park1, YH
EUR J CANCER 2017 10.1016/j.ejca.2017.10.002
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park1, YH; Im, SA; Kim, SB; Sohn, JH; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, JY; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH
NAT COMMUN 2017 10.1038/s41467-017-01470-y
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY
ONCOTARGET 2017 10.18632/oncotarget.21198
Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy
Kim1, JY; Park, D; Son, DS; Nam, SJ; Kim, SW; Jung, HH; Kim, YJ; Park, G; Park, WY; Lee, JE; Park, YH
BREAST 2017 10.1016/j.breast.2017.07.006
Isolated pachymeningeal metastasis from breast cancer: Clinical features and prognostic factors
Heo1, MH; Cho, YJ; Kim, HK; Kim, JY; Park, YH
BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy
Kim1, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH
ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12652
Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy
Kim1, H; Park, W; Huh, SJ; Choi, DH; Noh, JM; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Cho, EY
ONCOTARGET 2017 10.18632/oncotarget.17653
Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
Kim1, JY; Lee, E; Park, K; Park, WY; Jung, HH; Ahn, JS; Im, YH; Park, YH
Nat Commun. 2017 May 5;8:15081. doi: 10.1038/ncomms15081.
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung W11,2, Eum HH1,3, Lee HO1,4, Lee KM5,6, Lee HB5,7, Kim KT1, Ryu HS8, Kim S9, Lee JE9, Park YH10, Kan Z11, Han W5,7, Park WY1,2,4.
Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
Kim JY11, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.
Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3.
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Park YH11, Kim TY2, Im YH1, Lee KS3, Park IH3, Sohn J4, Lee SH4, Im SA2, Kim JH5, Kim SH5, Lee SJ6, Koh SJ7, Lee KH8, Choi YJ9, Cho EK10, Lee S11, Kang SY12, Seo JH13, Kim SB14, Jung KH14.
Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6.
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
Park KH11, Lee S2, Park JH3, Kang SY4, Kim HY5, Park IH6, Park YH7, Im YH7, Lee HJ8, Park S9, Lee SI10, Jung KH11, Kim YS12, Seo JH13.
TRANSLATIONAL CANCER RESEARCH, FEB 2017, 6:S42-S43, DOI: 10.21037/tcr.2017.02.19
Defining the subset of the patients in whom "Less is More" for hormone receptor-positive breast cancer: clinical risk vs. genomics risk
1,Park YH
Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.
The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
Kim JY11, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.
PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016.
The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
Lee JY11, Lim SH1, Lee MY1, Kim HS1, Ahn JS1, Im YH1, Park YH1.
BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Kim JY11, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.
Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11.
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems
Choi M11, Park YH2, Ahn JS2, Im YH2, Nam SJ3, Cho SY4, Cho EY5.
Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11.
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Kim HK11, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.
PLoS One. 2016 Oct 31;11(10):e0165814. doi: 10.1371/journal.pone.0165814. eCollection 2016.
Body Mass Index with Tumor F-18-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer
Hyun SH11, Ahn HK2, Lee JH1, Choi JY1, Kim BT1, Park YH3, Im YH3, Lee JE4, Nam SJ4, Lee KH1.
Cancer Res Treat. 2016 Oct;48(4):1373-1381. Epub 2016 Mar 23.
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
Kim SH11, Jung KH2, Kim TY3, Im SA3, Choi IS4, Chae YS5, Baek SK6, Kang SY7, Park S8, Park IH9, Lee KS9, Choi YJ10, Lee S11, Sohn JH11, Park YH12, Im YH12, Ahn JH2, Kim SB2, Kim JH1.
Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18.
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Kim JY11, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.
Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035.
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
Jung HH11, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.
PLoS One. 2016 Sep 20;11(9):e0163254. doi: 10.1371/journal.pone.0163254. eCollection 2016.
Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series
Lee MY11, Chang WJ1, Kim HS1, Lee JY1, Lim SH1, Lee JE2, Kim SW2, Nam SJ2, Ahn JS1, Im YH1, Park YH1.
Oncol Lett. 2016 Aug;12(2):1620-1622. Epub 2016 Jun 29.
Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients
Park JH11, Pahk K2, Kim S3, Lim SM4, Cheon GJ5, Park YH6, Lee SS7, Choe JG2.
SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804
The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
Kim JY1, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH
Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623.
Gene Expression Profiling of Breast Cancer Brain Metastasis
Lee JY11, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.
J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24.
Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes
Kim SW11, Choi DH2, Huh SJ2, Park W2, Nam SJ3, Kim SW3, Lee JE3, Im YH4, Ahn JS4, Park YH4.
Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11.
Limited Supraclavicular Radiation Field in Breast Cancer With >= 10 Positive Axillary Lymph Nodes
Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.
Korean J Radiol. 2015 Sep-Oct;16(5):986-95. doi: 10.3348/kjr.2015.16.5.986. Epub 2015 Aug 21.
Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype
Ko ES11, Han H2, Han BK1, Kim SM3, Kim RB4, Lee GW5, Park YH6, Nam SJ7.
Oncotarget. 2015 Sep 15;6(27):24499-510.
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
Park K11, Choi MK2, Jung HH3, Do IG4, Lee KH5, Ahn T1, Kil WH6, Kim SW6, Lee JE6, Nam SJ6, Kim DH7, Ahn JS2, Im YH2,3, Park YH2,3.
Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18.
Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments
Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.
Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192.
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer
Lee JY11, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.
Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13.
Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer
Lee JY11, Lim SH1, Lee MY1, Kim H1, Kim M1, Kim S1, Jung HA1, Sohn I2, Gil WH3, Lee JE3, Kim SW3, Nam SJ3, Ahn JS1, Im YH1, Park YH1.
Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184.
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
Park YH11,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.
Ann Surg Oncol. 2015 Oct;22(11):3481-8. doi: 10.1245/s10434-015-4399-1. Epub 2015 Feb 5.
The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women
Kim J11, Han W2, Jung SY3, Park YH4, Moon HG5, Ahn SK6, Lee JW7, Kim MK5, Kim JJ5, Lee ES5, You TK1, Kang HS3, Lee ES3, Ro J3, Lee JE4, Nam SJ4, Yim YH4, Park IA5, Noh DY5.
BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9.
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
Lee SJ11, Kim S2, Kim M3, Lee J4, Park YH5, Im YH6, Park SH7.
Breast Cancer Res Treat. 2015 Aug;152(3):675-82. doi: 10.1007/s10549-015-3502-4. Epub 2015 Jul 22.
Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study
Kang D11, Kim IR, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Park H, Kim E, Lee HK, Lee DY, Cho J.
Breast Cancer Res Treat. 2015 Jul;152(1):77-85. doi: 10.1007/s10549-015-3450-z. Epub 2015 Jun 2.
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
Park YH11, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS; Korean Cancer Study Group (KCSG), Im YH.
J Breast Cancer. 2015 Jun;18(2):195-9. doi: 10.4048/jbc.2015.18.2.195. Epub 2015 Jun 26.
Dermatomyositis and Paclitaxel-Induced Cutaneous Drug Eruption Associated with Metastatic Breast Cancer
Kim Y11, Jung W1, Park YH2.
Breast. 2015 Jun;24(3):213-7. doi: 10.1016/j.breast.2015.01.012. Epub 2015 Feb 24.
Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea
Park YH11, Lee SJ1, Jung HA1, Kim SM1, Kim MJ1, Kil WH2, Lee JE2, Nam SJ2, Ahn JS1, Im YH3.
Radiology. 2015 Apr;275(1):235-44. doi: 10.1148/radiol.14141129. Epub 2014 Dec 11.
Volume-based Metabolic Tumor Response to Neoadjuvant Chemotherapy Is Associated with an Increased Risk of Recurrence in Breast Cancer
Hyun SH11, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, Nam SJ, Cho EY, Choi JY.
Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24.
A seven-gene signature can predict distant recurrence in patients with triple- negative breast cancers who receive adjuvant chemotherapy following surgery
Park YH11, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH.
J Breast Cancer. 2015 Mar;18(1):50-6. doi: 10.4048/jbc.2015.18.1.50. Epub 2015 Mar 27.
Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer
Yu JI11, Choi DH1, Huh SJ1, Park W1, Nam SJ2, Kim SW2, Lee JE2, Kil WH2, Im YH3, Ahn JS3, Park YH3.
Tumour Biol. 2015 Feb;36(2):1073-9. doi: 10.1007/s13277-014-2730-2. Epub 2014 Oct 19.
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology
Jung HA11, Park YH, Kim M, Kim S, Chang WJ, Choi MK, Hong JY, Kim SW, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH.
Ann Oncol. 2014 Feb;25(2):346-51. doi: 10.1093/annonc/mdt476. Epub 2013 Dec 29.
Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients
Cho J11, Choi EK, Kim IR, Im YH, Park YH, Lee S, Lee JE, Yang JH, Nam SJ.
J Breast Cancer. 2014 Dec;17(4):308-13. doi: 10.4048/jbc.2014.17.4.308. Epub 2014 Dec 26.
Meeting Highlights: The First Korean Breast Cancer Treatment Consensus Conference
Han A11, Lee KE2, Lee HK3, Park YH4, Kim J5, Kim SW6, Jung KH7, Son BH8; Korean Breast Cancer Treatment Consensus Conference Panelists.
Asian Pac J Cancer Prev. 2014;15(20):8607-12.
Association between Socioeconomic Status and Altered Appearance Distress, Body Image, and Quality of Life Among Breast Cancer Patients
Chang O11, Choi EK, Kim IR, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Cho J.
Psychooncology. 2014 Oct;23(10):1103-10. doi: 10.1002/pon.3531. Epub 2014 Mar 24.
Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients
Choi EK11, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Yang JH, Cho J.
Cancer?Chemother Pharmacol.?2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22.
Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer
Choi MK11,?Park YH,?Kil WH,?Lee JE,?Nam SJ,?Ahn JS,?Im YH.
Oncology.?2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.
Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers
Park YH11,?Im SA,?Cho EY,?Ahn JH,?Woo SY,?Kim S,?Keam B,?Lee JE,?Han W,?Nam SJ,?Park IA,?Noh DY,?Yang JH,?Ahn JS,?Im YH.
Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22.
Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma
Park LC11, Jeong JY2, Ji JH3, Park S3, Ahn JS3, Im YH3, Park YH3.
Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18.
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
Lee SY11, Im SA2, Park YH3, Woo SY4, Kim S4, Choi MK5, Chang W5, Ahn JS5, Im YH5.
Br J?Cancer.?2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17.
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
Park YH11,?Jung HA1,?Choi MK1,?Chang W1,?Choi YL2,?Do IG2,?Ahn JS1,?Im YH1.
Invest New Drugs. 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16.
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer
Park KH11, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH.
Biochem Biophys Res Commun.?2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21.
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway
Park YH11,?Jung HH,?Ahn JS,?Im YH.
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
Cancer Res Treat. 2013 Mar;45(1):70-3. doi: 10.4143/crt.2013.45.1.70. Epub 2013 Mar 31.
A Case Report of Paraneoplastic Pemphigus Associated with Esophageal Squamous Cell Carcinoma
Cho JH11, Kim NJ, Ko SM, Kim C, Ahn HK, Yun J, Park YH.
Acta Oncol. 2013 Jan;52(1):73-81. doi: 10.3109/0284186X.2012.731520. Epub 2012 Oct 17.
Prognostic impact of FOXP3 expression in triple-negative breast cancer
Lee S11, Cho EY, Park YH, Ahn JS, Im YH.
Br J Cancer. 2012 Sep 25;107(7):1075-82. doi: 10.1038/bjc.2012.346. Epub 2012 Aug 23.
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
Yap YS11, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, Lee SC, Park YH, Sohn JH, Sutandyo N, Wong DW, Kobayashi M, Landis SH, Yeoh EM, Moon H, Ro J.
Breast?Cancer Res Treat.?2012 May;133(1):247-55. doi: 10.1007/s10549-012-1956-1. Epub 2012 Jan 21.
Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy
Park YH11,?Im SA,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Ahn JS,?Im YH.
Ann Oncol.?2011 Jul;22(7):1554-60. doi: 10.1093/annonc/mdq617. Epub 2011 Jan 17.
Clinical relevance of TNM staging system according to breast cancer subtypes
Park YH11,?Lee SJ,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Shin JH,?Ko EY,?Han BK,?Ahn JS,?Im YH.
Tumour Biol. 2011 Feb;32(1):45-51. doi: 10.1007/s13277-010-0089-6. Epub 2010 Aug 10.
Clinical presentation of carcinoma of unknown primary: 14 years of experience
Yi JH11, La Choi Y, Lee SJ, Ahn HK, Baek KK, Lim T, Lee DJ, Han BR, Lee HY, Jun HJ, Lee J, Park YH.
Breast Cancer Res Treat. 2011 Jan;125(1):99-106. doi: 10.1007/s10549-010-1201-8. Epub 2010 Oct 5.
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
Kim JE11, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY.
CA 15-3 kinetics: clinical implication of CA 15-3 surge in metastatic breast cancer
Med Oncol.?2010 Dec;27(4):1234-8. doi: 10.1007/s12032-009-9364-z. Epub 2009 Nov 19.
Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)
Choi MK11,?Park YH,?Hong JY,?Park HC,?Ahn YC,?Kim K,?Shim YM,?Kang WK,?Park K,?Im YH.
Br J Cancer.?2010 Sep 7;103(6):845-51. doi: 10.1038/sj.bjc.6605831. Epub 2010 Aug 10.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
Lee S11,?Park YH,?Kim KH,?Cho EY,?Ahn YC,?Kim K,?Shim YM,?Ahn JS,?Park K,?Im YH.
Oral Oncol. 2010 Aug;46(8):607-11. doi: 10.1016/j.oraloncology.2010.05.005. Epub 2010 Jul 8.
Role of adjuvant chemotherapy in malignant mucosal melanoma of the head and neck
Ahn HJ11, Na II, Park YH, Cho SY, Lee BC, Lee GH, Koh JS, Lee YS, Shim YS, Kim YK, Kang HJ, Ryoo BY, Yang SH.
Cancer?Chemother Pharmacol.?2010 Aug;66(3):507-16. doi: 10.1007/s00280-009-1190-7. Epub 2009 Dec 3.
Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status
Park YH11,?Lee S,?Cho EY,?Choi YL,?Lee JE,?Nam SJ,?Yang JH,?Ahn JS,?Im YH.
Mol Cancer Res.?2010 Jul;8(7):1037-47. doi: 10.1158/1541-7786.MCR-09-0469. Epub 2010 Jun 15.
Matrix Metalloproteinase-1 Expression Can Be Upregulated through Mitogen-Activated Protein Kinase Pathway under the Influence of Human Epidermal Growth Factor Receptor 2 Synergized with Estrogen Receptor
Jung HH11,?Park YH,?Jun HJ,?Kong J,?Kim JH,?Kim JA,?Yun J,?Sun JM,?Won YW,?Lee S,?Kim ST,?Ahn JS,?Im YH.
Bone Marrow Transplant. 2010 Mar;45(3):550-7. doi: 10.1038/bmt.2009.185. Epub 2009 Aug 3.
Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors
Han TH11, Tang Y, Park YH, Maynard J, Li P, Akbulut H, Petersen L, Deisseroth A.
Cancer. 2010 Feb 1;116(3):676-85. doi: 10.1002/cncr.24748.
Clinical Impact of Phosphorylated Signal Transducer and Activator of Transcription 3, Epidermal Growth Factor Receptor, p53, and Vascular Endothelial Growth Factor Receptor I Expression in Resected Adenocarcinoma of Lung by Using Tissue Microarray
Kim HS11, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ.
Breast?Cancer?Res Treat.?2010 Feb;119(3):653-61. doi: 10.1007/s10549-009-0665-x.
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (<= 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment
Park YH11,?Kim ST,?Cho EY,?Choi YL,?Ok ON,?Baek HJ,?Lee JE,?Nam SJ,?Yang JH,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Im YH.
Breast Cancer?Res Treat.?2009 Nov;118(1):89-97. doi: 10.1007/s10549-009-0377-2. Epub 2009 Mar 26.
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Kim HS11,?Park YH,?Park MJ,?Chang MH,?Jun HJ,?Kim KH,?Ahn JS,?Kang WK,?Park K,?Im YH.
Drug Therapy for Breast Cancer
Br J?Cancer.?2009 Mar 24;100(6):894-900. doi: 10.1038/sj.bjc.6604941. Epub 2009 Feb 24.
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
Park YH11,?Park MJ,?Ji SH,?Yi SY,?Lim DH,?Nam DH,?Lee JI,?Park W,?Choi DH,?Huh SJ,?Ahn JS,?Kang WK,?Park K,?Im YH.
Int J?Cancer.?2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090.
Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
Uhm JE11,?Park YH,?Yi SY,?Cho EY,?Choi YL,?Lee SJ,?Park MJ,?Lee SH,?Jun HJ,?Ahn JS,?Kang WK,?Park K,?Im YH.
Clin Cancer Res. 2009 Mar 15;15(6):2107-15. doi: 10.1158/1078-0432.CCR-08-1588. Epub 2009 Mar 10.
Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy
Park YH11, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH.
Biochem Biophys Res Commun.?2008 Dec 12;377(2):389-94. doi: 10.1016/j.bbrc.2008.09.135. Epub 2008 Oct 11.
Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells
Park YH11,?Jung HH,?Ahn JS,?Im YH.
J Med Virol. 2008 Jun;80(6):960-6. doi: 10.1002/jmv.21168.
High prevalence of hepatitis B virus infection in patients with B-Cell non-Hodgkin's lymphoma in Korea
Park SC11, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, Cho JH, Lee M, Jung HH, Ki SS, Chang YH, Lee SS, Park YH, Lee KH.
Cancer Chemother Pharmacol. 2008 Feb;61(2):301-7. Epub 2007 Apr 12.
Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy
Kim JG11, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK.
Cancer Lett. 2007 Dec 8;258(1):90-7.
Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study
Oh SY11, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ.
Leukemia. 2007 Oct;21(10):2227-30. Epub 2007 Jun 7.
Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma
Kim DH1, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK.
Eur J Haematol. 2007 Oct;79(4):287-91. Epub 2007 Aug 10.
Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease
Oh SY11, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ.
Br J Haematol. 2007 May;137(4):329-36. Epub 2007 Apr 4.
Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas
Lee JJ11, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH.
Eur J Haematol. 2006 Oct;77(4):304-8. Epub 2006 Jul 27.
Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma
Park YH11, Kim WS, Bang SM, Lee SI, Uhm JE, Kang HJ, Na II, Yang SH, Lee SS, Kim K, Jung CW, Park K, Ko YH, Ryoo BY.
Leuk Res. 2006 Oct;30(10):1253-8. Epub 2006 Mar 9.
Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome
Park YH11, Kim WS, Bang SM, Lee SI, Kang HJ, Na II, Yang SH, Lee SS, Uhm JE, Kwon JM, Kim K, Jung CW, Park K, Ko YH, Ryoo BY.
Leuk Lymphoma. 2006 Oct;47(10):2011-2.
What is the best treatment for primary breast lymphoma Combined modality should be adapted according to the risk stratification
1,Park YH1.
Blood. 2006 Oct 15;108(8):2720-5. Epub 2006 Apr 11.
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Kim DH11, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK.
